Dogwood Therapeutics develops new medicines for pain and neuropathic disorders as a development-stage biopharmaceutical company listed on Nasdaq under DWTX. Company news centers on its pain and neuropathy pipeline, including Halneuron®, a non-opioid NaV 1.7 analgesic in development for chemotherapy-induced neuropathic pain, and SP16 IV, an LRP1 agonist program for chemotherapy-related pain and neuropathy.
Recurring updates also cover clinical and regulatory developments, FDA designations and investigational-drug activity, intellectual-property work tied to synthetic Halneuron®, financial results, financing activity, shareholder communications, and licensing arrangements involving anti-viral assets such as IMC-1 and IMC-2.
Dogwood Therapeutics (NASDAQ: DWTX) entered a global development and commercialization partnership with PRIDCor for antiviral candidates IMC-1 and IMC-2 dated April 23, 2026. PRIDCor will finance development; Dogwood is entitled to a tiered royalty up to 15%, 9% of future PRIDCor capital for these assets, and potential payments capped at $100 million. Dogwood will focus internally on Halneuron and SP16. Payments that qualify as CVR-related will be passed to CVR holders as required.
Dogwood Therapeutics (NASDAQ: DWTX) announced FDA acceptance of an IND for SP16, an IV candidate to treat chemotherapy-induced pain and peripheral neuropathy (CIPPN). Serpin Pharma is regulatory sponsor; a $2.5 million NCI grant will fully fund the planned Phase 1b trial, with enrollment expected mid-2026.
Dogwood holds a royalty-free global license to Serpin’s IV SP16 formulation acquired in September 2025.
Dogwood Therapeutics (Nasdaq: DWTX) reported Q4 and full-year 2025 results and clinical updates. Key items: interim Phase 2b analysis showed Halneuron® separating from placebo in a 97-patient subset; 143 patients recruited; trial >50% enrolled with top-line data expected in Q3 2026. The company completed a financing of up to $26.9M, receiving $12.5M gross and $11.4M net in Jan 2026, and had $6.5M cash at Dec 31, 2025, expected to fund operations into Q4 2026.
Full-year R&D rose to $21.8M vs $3.5M in 2024; net loss was $35.5M or $7.13 per share.
Dogwood Therapeutics (Nasdaq: DWTX) announced it has reached over 50% enrollment in the HALT-CINP Phase 2b trial of Halneuron® for chemotherapy-induced neuropathic pain and remains on track for top-line results in Q3 2026.
An independent review of an earlier interim cohort reported separation from placebo on pain improvement and a low overall dropout rate (~4%). The randomized trial enrolls at ~30 U.S. sites with a 28-day follow-up and primary endpoint at week four.
Dogwood Therapeutics (NASDAQ: DWTX) announced registered and private offerings to raise up to $12.5 million in upfront gross proceeds and the potential for an additional $14.4 million upon warrant exercises, for aggregate financings tied to issuance of 4,386,037 common shares (or pre-funded warrants) and detachable warrants. Securities are priced at-the-market under Nasdaq rules at a combined purchase price of $2.85 and warrant exercise price of $3.28. Proceeds are earmarked to advance Halneuron through Phase 2b final readout and support further development and working capital.
Dogwood Therapeutics (Nasdaq: DWTX) reported a positive interim analysis from 97 patients in its Phase 2b study of Halneuron for chemotherapy induced neuropathic pain (CINP) on Dec 22, 2025. An independent committee found Halneuron-treated patients separated from placebo on pain improvement over four weeks. The company projects top-line results in Q3 2026 and enrollment trends that provide ~80%–85% statistical power. The interim cohort had an average CINP duration of 5 years, with 67% on stable background pain meds; overall dropout was ~4.4%. The company says safety and tolerability remain encouraging, and positive Phase 2b outcomes could support a Phase 3 registration program.
Dogwood Therapeutics (Nasdaq: DWTX) filed a new composition of matter intellectual property application for a fully synthetically manufactured Halneuron® on December 2, 2025. The company says the synthetic process delivers higher manufacturing yields and lower costs versus naturally harvested Halneuron® and is planned for use in Phase 3 development and commercialization. If the IP is granted, Dogwood projects the exclusivity period could extend to 2045, before any additional patent term restoration.
Dogwood (Nasdaq:DWTX) announced it has enrolled the first 100 patients in the HALT-CINP Phase 2b trial of Halneuron® for chemotherapy-induced neuropathic pain as of November 11, 2025. The company says early termination rates remain low among the first 80 completers, suggesting tolerability. A prespecified interim sample-size analysis is on track for Q4 2025 to evaluate whether the planned 200-patient sample remains adequate. The study randomizes patients to Halneuron® or placebo, delivers 8 subcutaneous doses over 14 days, follows patients for 28 days, and is running at ~25 US sites, with final data targeted for mid-2026.
Dogwood Therapeutics (Nasdaq: DWTX) reported Q3 2025 results and strategic updates on Nov 6, 2025. Key operational items: 100 patients enrolled in the Halneuron® Phase 2b trial with 80 completing treatment, and the prespecified interim analysis remains on track for Q4 2025 with final 200‑patient data expected in H2 2026. The company closed an exclusive worldwide, royalty‑free license to develop SP16 in an all‑stock transaction. Financials: Q3 R&D expense was $14.5M (vs $0.5M prior year) driven by a $12.0M acquired in‑process R&D charge; net loss was $15.7M or $8.20 per share. Cash of $10.1M provides runway through Q1 2026.
Dogwood Therapeutics (Nasdaq:DWTX) announced it will report third quarter 2025 financial results on Thursday, November 6, 2025 before market open.
The company is a development-stage biotechnology firm focused on new medicines to treat pain and neuropathy. No financial metrics or guidance were included in the announcement.